---
title: "CF PHARMTECH's candidate drug ICF00 clinical trial application has been accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279070595.md"
description: "CF PHARMTECH announced that its self-developed inhalation powder candidate drug ICF001 has been accepted for clinical trial application by the National Medical Products Administration of China. ICF001 is an innovative long-acting inhalation powder candidate drug developed based on a prodrug technology platform, specifically designed for the treatment of pulmonary arterial hypertension and related severe pulmonary diseases"
datetime: "2026-03-13T16:08:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279070595.md)
  - [en](https://longbridge.com/en/news/279070595.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279070595.md)
---

# CF PHARMTECH's candidate drug ICF00 clinical trial application has been accepted

CF PHARMTECH (02652.HK) announced that its self-developed inhalation powder candidate drug ICF001 has been accepted for clinical trial application by the National Medical Products Administration of China. ICF001 is an innovative long-acting inhalation powder candidate drug developed based on a prodrug technology platform, specifically designed for the treatment of pulmonary arterial hypertension and related severe pulmonary diseases

### Related Stocks

- [02652.HK](https://longbridge.com/en/quote/02652.HK.md)

## Related News & Research

- [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md)
- [10:00 ETAMIA Amplify Poster Session: FDB Pharmacists Show Patient-Specific Medication Guidance Can Reduce Pharmacy Alerts by 70%](https://longbridge.com/en/news/286578656.md)
- [Apnimed's sleep apnea pill meets main goal in late-stage study](https://longbridge.com/en/news/286785038.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)
- [Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026](https://longbridge.com/en/news/286795160.md)